Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-6 in transplant-ineligible newly diagnosed multiple myeloma
jRCT2021220036Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of elranatamab, daratumumab, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (5 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity, Progression-free survival per IMWG and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
elranatamabdaratumumablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220036.